ijms-logo

Journal Browser

Journal Browser

State-of-the-Art Molecular Oncology in Brazil, 3rd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 1774

Special Issue Editors


E-Mail Website1 Website2
Guest Editor
Centro de Ciências Naturais e Humanas (CCNH), Universidade Federal do ABC (UFABC), Santo André 09210-580, Brazil
Interests: apoptosis; autophagy; calcium; cancer; chemotherapy; mitochondria; oxidative stress; drug development
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Center for Translational Research in Oncology (LIM24), Department of Radiology and Oncology, Faculdade de Medicina da Universidade de São Paulo, São Paulo 01246-903, Brazil
Interests: carbohydrate-dependent cellular interactions; tumor microenvironment; chemo- and radiotherapy; extracellular vesicles; tumor-associated macrophages; novel therapeutic cargo to tumors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue follows the publication of the third edition on the topic “State-of-the-Art Molecular Oncology in Brazil”.

https://www.mdpi.com/journal/ijms/special_issues/Mol_Oncol_BR

https://www.mdpi.com/journal/ijms/special_issues/JKE9Y113YO

Cancer is a broad term to describe a large number of diseases characterized by the transformation of normal to abnormal tumor cells with uncontrolled proliferative capacity as a result of mutations, epigenetic alterations, exposure to toxicants and environmental conditions, as well as others. Tumor cells exhibit several molecular, morphological, and functional alterations, giving them proliferative advantages, the ability to escape from the immune system and cell death, and invasiveness capacity. In this regard, many studies focused on the molecular aspects of cancer have been conducted worldwide, aiming to improve our current understanding of tumor cell functioning, to describe molecular mechanisms of therapeutic options, and to discover novel targets and drugs for cancer treatment.

This Special Issue aims to highlight recent advances in cancer research in Brazil, focused on the molecular aspects of cancer. It includes studies conducted to unveil the molecular alterations exhibited by tumor cells, the proposal of novel targets for cancer therapy, and the mechanisms of action of drugs and drug candidates (including off-target effects and drug repurposing).

Thus, in order to provide a comprehensive view of recent advances in cancer research in Brazil, we invite researchers to submit original research papers and high-quality comprehensive reviews in the cancer research field to this Special Issue. Potential topics include but are not limited to the following:

  • Molecular aspects of tumorigenesis;
  • Mechanisms of evasion of cell death (apoptosis, necroptosis, autophagy, and others);
  • Ionic and metabolic alterations in cancer;
  • Molecular aspects of cancer therapy (mechanisms of drugs and drug candidates and new targets);
  • Drug resistance mechanisms in cancer therapy.

Dr. Tiago Rodrigues
Prof. Dr. Roger Chammas
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • apoptosis
  • autophagy
  • calcium
  • cancer
  • cell death
  • chemotherapy
  • metabolism
  • mitochondria
  • drug resistance
  • oxidative stress

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 3881 KiB  
Article
DLK1 Is Associated with Stemness Phenotype in Medullary Thyroid Carcinoma Cell Lines
by Danilo Dias da Silva, Rodrigo Pinheiro Araldi, Mariana Rocha Belizario, Welbert Gomes Rocha, Rui Monteiro de Barros Maciel and Janete Maria Cerutti
Int. J. Mol. Sci. 2024, 25(22), 11924; https://doi.org/10.3390/ijms252211924 - 6 Nov 2024
Viewed by 417
Abstract
Medullary thyroid carcinoma (MTC) is a rare and aggressive tumor, often requiring systemic treatment in advanced or metastatic stages, where drug resistance presents a significant challenge. Given the role of cancer stem cells (CSCs) in cancer recurrence and drug resistance, we aimed to [...] Read more.
Medullary thyroid carcinoma (MTC) is a rare and aggressive tumor, often requiring systemic treatment in advanced or metastatic stages, where drug resistance presents a significant challenge. Given the role of cancer stem cells (CSCs) in cancer recurrence and drug resistance, we aimed to identify CSC subpopulations within two MTC cell lines harboring pathogenic variants in the two most common MEN2-associated codons. We analyzed 15 stemness-associated markers, along with well-established thyroid stem cell markers (CD133, CD44, and ALDH1), a novel candidate (DLK1), and multidrug resistance proteins (MRP1 and MRP3). The ability to efflux the fluorescent dye Hoechst 3342 and form spheroids, representing CSC behavior, was also assessed. MZ-CRC-1 cells (p.M918T) displayed higher expressions of canonical markers, DLK1, and MRP proteins than TT cells (p.C634W). MZ-CRC-1 cells also formed more spheroids and showed less dye accumulation (p < 0.0001). Finally, we observed that DLK1+ cells (those expressing DLK1) in both cell lines exhibited significantly higher levels of stemness markers compared to DLK1− cells (those lacking DLK1 expression). These findings underscore DLK1’s role in enhancing the stemness phenotype, providing valuable insights into MTC progression and resistance and suggesting potential therapeutic implications. Full article
(This article belongs to the Special Issue State-of-the-Art Molecular Oncology in Brazil, 3rd Edition)
Show Figures

Figure 1

16 pages, 2129 KiB  
Article
Metabolomic Profiling of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy for Predicting Disease-Free and Overall Survival
by Maria Cecília Ramiro Talarico, Sophie Derchain, Lucas Ferreira da Silva, Maurício L. Sforça, Silvana A. Rocco, Marcella R. Cardoso and Luís Otávio Sarian
Int. J. Mol. Sci. 2024, 25(16), 8639; https://doi.org/10.3390/ijms25168639 - 8 Aug 2024
Viewed by 973
Abstract
Breast cancer (BC) remains a significant global health concern, with neoadjuvant chemotherapy (NACT) offering preoperative benefits like tumor downstaging and treatment response assessment. However, identifying factors influencing post-NACT treatment response and survival outcomes is challenging. Metabolomic approaches offer promising insights into understanding these [...] Read more.
Breast cancer (BC) remains a significant global health concern, with neoadjuvant chemotherapy (NACT) offering preoperative benefits like tumor downstaging and treatment response assessment. However, identifying factors influencing post-NACT treatment response and survival outcomes is challenging. Metabolomic approaches offer promising insights into understanding these outcomes. This study analyzed the serum of 80 BC patients before and after NACT, followed for up to five years, correlating with disease-free survival (DFS) and overall survival (OS). Using untargeted nuclear magnetic resonance (NMR) spectroscopy and a novel statistical model that avoids collinearity issues, we identified metabolic changes associated with survival outcomes. Four metabolites (histidine, lactate, serine, and taurine) were significantly associated with DFS. We developed a metabolite-related survival score (MRSS) from these metabolites, stratifying patients into low- and high-risk relapse groups, independent of classical prognostic factors. High-risk patients had a hazard ratio (HR) for DFS of 3.42 (95% CI 1.51–7.74; p = 0.003) after adjustment for disease stage and age. A similar trend was observed for OS (HR of 3.34, 95% CI 1.64–6.80; p < 0.001). Multivariate Cox proportional hazards analysis confirmed the independent prognostic value of the MRSS. Our findings suggest the potential of metabolomic data, alongside traditional markers, in guiding personalized treatment decisions and risk stratification in BC patients undergoing NACT. This study provides a methodological framework for leveraging metabolomics in survival analyses. Full article
(This article belongs to the Special Issue State-of-the-Art Molecular Oncology in Brazil, 3rd Edition)
Show Figures

Figure 1

Back to TopTop